In recent years, several antagonists of alpha(nu)beta(3), have been used to
develop therapeutic approaches to the treatment of melanoma neoplasia. We
studied the effects of anti-alpha(nu)-integrin-blocking antibodies on attac
hed M21 melanoma cells, the cellular distribution of alpha(nu)-integrin and
the molecular organization of focal structures. Anti-alpha(nu)-integrin-bl
ocking antibodies 17E6 and LM609, and an anti-alpha(nu)beta(3)-integrin ant
agonist peptide cRGD 85189 induced detachment of M21 melanoma cells culture
d for 24 hours on various substrates. cRGD was the most effective antagonis
t, reducing the number of adherent cells by 80%, while 17E6 reduced adhesio
n by only 30%. Light- and electron microscopy revealed attached cells with
a flat shape and well-formed actin cytoskeleton. After treatment, cells bec
ame rounded and detached from the culture dish. alpha(nu)-Integrins and foc
al-contact proteins were observed at adhesion sites in focal structures by
immunocytochemistry. After treatment, however, cell rounding was accompanie
d by disorganization of the actin filaments and redistribution of alpha(nu)
-integrins and most of the focal proteins studied, except vinculin and tens
in. Our results indicate that treatment of M21 melanoma cells with alpha(nu
)-integrin antagonists disrupts the actin cytoskeleton, redistributes alpha
(nu)-integrin and induces molecular disassembly of focal contacts.